clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02831179 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P582 | end time | 2019-02-01 | |
P1050 | medical condition | carcinoma | Q33525 |
gastrinoma | Q786852 | ||
adrenocortical carcinoma | Q918285 | ||
insulinoma | Q1501239 | ||
VIPoma | Q1518637 | ||
multiple endocrine neoplasia | Q1553018 | ||
somatostatinoma | Q1736456 | ||
multiple endocrine neoplasia type 1 | Q3347154 | ||
Zollinger–Ellison syndrome | Q218712 | ||
multiple endocrine neoplasia type 2A | Q604075 | ||
multiple endocrine neoplasia type 2B | Q624748 | ||
glucagonoma | Q770843 | ||
P2899 | minimum age | 18 | |
P1132 | number of participants | 0 | |
P8329 | principal investigator | Jordan D. Berlin | Q91134026 |
P4844 | research intervention | veliparib | Q7919041 |
P580 | start time | 2017-12-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors |
Search more.